La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Schrödinger Gestione

Gestione criteri di controllo 4/4

Schrödinger's Il CEO è Ramy Farid, nominato in Jan2008, e ha un mandato di 16.58 anni. la retribuzione annua totale è $ 3.12M, composta da 21.7% di stipendio e 78.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.25% delle azioni della società, per un valore di $ 3.78M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6.8 anni e 5.3 anni.

Informazioni chiave

Ramy Farid

Amministratore delegato

US$3.1m

Compenso totale

Percentuale dello stipendio del CEO	21.7%
Mandato del CEO	16.6yrs
Proprietà del CEO	0.3%
Durata media del management	6.8yrs
Durata media del Consiglio di amministrazione	5.3yrs

Aggiornamenti recenti sulla gestione

We Think The Compensation For Schrödinger, Inc.'s (NASDAQ:SDGR) CEO Looks About Right

Jun 12

Recent updates

Schrodinger: More Drug Discovery Validation

Aug 06

Here's Why We're Watching Schrödinger's (NASDAQ:SDGR) Cash Burn Situation

Aug 05

We Think The Compensation For Schrödinger, Inc.'s (NASDAQ:SDGR) CEO Looks About Right

Jun 12

Schrödinger: More Pharmaceutical Than Software

May 07

Schrödinger, Inc. (NASDAQ:SDGR) Not Flying Under The Radar

May 02

Schrödinger, Inc. (NASDAQ:SDGR) Analysts Just Cut Their EPS Forecasts Substantially

Mar 01

Is There An Opportunity With Schrödinger, Inc.'s (NASDAQ:SDGR) 49% Undervaluation?

Jul 01

Schrödinger: Q2 Earnings Supports Growth Narrative

Aug 26

Schrödinger appoints Dr. Geoffrey Porges as finance chief

Aug 18

Sizing Up Schrodinger

Jun 06

Schrödinger: Holding The Keys To Discovery

Mar 26

Schrodinger: A Long-Term Hold For Biotech Investors With Upside Potential Too

Mar 15

Schrödinger: Conviction Remains High, Q4 Report And Guidance Will Be Critical

Jan 06

After Its Stock Price Doubled Last Year, Why Schrödinger Is Slumping Now

Nov 24

We're Interested To See How Schrödinger (NASDAQ:SDGR) Uses Its Cash Hoard To Grow

Nov 12

An Intrinsic Calculation For Schrödinger, Inc. (NASDAQ:SDGR) Suggests It's 38% Undervalued

Oct 05

Schrodinger: An Investment In Drug Discovery In Addition To Software Sales

Sep 20

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Ramy Farid rispetto agli utili di Schrödinger?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$201m
Mar 31 2024	n/a	n/a	-US$143m
Dec 31 2023	US$3m	US$677k	US$41m
Sep 30 2023	n/a	n/a	US$44m
Jun 30 2023	n/a	n/a	US$66m
Mar 31 2023	n/a	n/a	US$14m
Dec 31 2022	US$4m	US$651k	-US$149m
Sep 30 2022	n/a	n/a	-US$153m
Jun 30 2022	n/a	n/a	-US$148m
Mar 31 2022	n/a	n/a	-US$135m
Dec 31 2021	US$8m	US$620k	-US$100m
Sep 30 2021	n/a	n/a	-US$81m
Jun 30 2021	n/a	n/a	-US$42m
Mar 31 2021	n/a	n/a	-US$11m
Dec 31 2020	US$9m	US$526k	-US$24m
Sep 30 2020	n/a	n/a	-US$20m
Jun 30 2020	n/a	n/a	-US$35m
Mar 31 2020	n/a	n/a	-US$33m
Dec 31 2019	US$633k	US$478k	-US$25m
Sep 30 2019	n/a	n/a	-US$24m
Jun 30 2019	n/a	n/a	-US$24m
Mar 31 2019	n/a	n/a	-US$29m
Dec 31 2018	US$1m	US$464k	-US$28m

Compensazione vs Mercato: La retribuzione totale di Ramy ($USD 3.12M ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 5.64M ).

Compensazione vs guadagni: La retribuzione di Ramy è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Ramy Farid (59 yo)

16.6yrs

Mandato

US$3,124,165

Compensazione

Dr. Ramy Farid, Ph.D. is Independent Director of Vir Biotechnology, Inc. from May 29, 2024. He serves as the President of Schrödinger, Inc. since January 2008 and has been its Chief Executive Officer since...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Ramy Farid	CEO, President & Director	16.6yrs	US$3.12m	0.25% $ 3.9m
Richard Friesner	Co-Founder	34yrs	US$1.09m	1.7% $ 26.2m
Geoffrey Porges	Executive VP & CFO	2yrs	US$1.65m	0.0078% $ 120.5k
Robert Abel	Executive VP	less than a year	US$1.70m	0.0020% $ 30.4k
Karen Akinsanya	President of Research & Development Therapeutics	6.3yrs	US$1.68m	0% $ 0
Margaret Han Dugan	Chief Medical Officer	1.1yrs	US$3.46m	Nessun dato
William Goddard	Co-Founder & Scientific Advisor	no data	Nessun dato	Nessun dato
Kenneth Lorton	Executive VP	7.3yrs	US$4.49m	0.049% $ 761.8k
Shane Brauner	Executive VP & Chief Information Officer	7.6yrs	Nessun dato	Nessun dato
Jaren Madden	Senior Vice President of Investor Relations & Corporate Communications	4.6yrs	Nessun dato	Nessun dato
Yvonne Tran	Corporate Secretary	14.6yrs	US$1.47m	0.0086% $ 132.9k
Mathew Halls	Senior Vice President of Materials Science	no data	Nessun dato	Nessun dato

6.8yrs

Durata media

54.5yo

Età media

Gestione esperta: Il team dirigenziale di SDGR è esperto e expertise (durata media dell'incarico 6.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Ramy Farid	CEO, President & Director	11.7yrs	US$3.12m	0.25% $ 3.9m
Richard Friesner	Co-Founder	34yrs	US$1.09m	1.7% $ 26.2m
William Goddard	Co-Founder & Scientific Advisor	no data	Nessun dato	Nessun dato
Michael Lynton	Independent Chairman of the Board	6.6yrs	US$727.05k	0.0086% $ 132.6k
Gary Ginsberg	Independent Director	4.3yrs	US$689.55k	0.0086% $ 132.6k
Gary Sender	Independent Director	5.1yrs	US$707.05k	0.0086% $ 132.6k
Vijay Pande	Scientific Advisor	no data	Nessun dato	Nessun dato
William Jorgensen	Scientific Advisor	no data	Nessun dato	Nessun dato
Rosana Kapeller-Libermann	Independent Director	5.6yrs	US$687.05k	0.0086% $ 132.6k
Brian Shoichet	Scientific Advisor	no data	Nessun dato	Nessun dato
Nancy Thornberry	Independent Director	4.9yrs	US$684.55k	0.0086% $ 132.6k
Jeffrey Chodakewitz	Independent Director	4.3yrs	US$692.05k	0.0086% $ 132.6k

5.3yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di SDGR sono considerati esperti (durata media dell'incarico 5.3 anni).

Schrödinger Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

We Think The Compensation For Schrödinger, Inc.'s (NASDAQ:SDGR) CEO Looks About Right

Schrödinger, Inc., Annual General Meeting, Jun 18, 2024

Executive VP & CTO notifies of intention to sell stock

Chief Legal & People Officer notifies of intention to sell stock

Independent Director exercised options and sold US$349k worth of stock

Insufficient new directors

Recent updates

Consensus EPS estimates upgraded to US$2.42 loss

Schrodinger: More Drug Discovery Validation

Here's Why We're Watching Schrödinger's (NASDAQ:SDGR) Cash Burn Situation

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Schrödinger, Inc. Provides Earnings Guidance for the Third Quarter of 2024 and Fiscal Year Ending December 31, 2024

Schrödinger, Inc. to Report Q2, 2024 Results on Jul 31, 2024

We Think The Compensation For Schrödinger, Inc.'s (NASDAQ:SDGR) CEO Looks About Right

Schrödinger: More Pharmaceutical Than Software

Schrödinger, Inc. Provides Earnings Guidance for the Second Quarter of 2024 and Fiscal Year Ending December 31, 2024

New minor risk - Profitability

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Schrödinger, Inc. (NASDAQ:SDGR) Not Flying Under The Radar

Schrödinger, Inc., Annual General Meeting, Jun 18, 2024

Schrödinger, Inc. to Report Q1, 2024 Results on May 01, 2024

Consensus revenue estimates fall by 18%

New minor risk - Share price stability

Schrödinger, Inc. (NASDAQ:SDGR) Analysts Just Cut Their EPS Forecasts Substantially

Schrodinger: Conservative Guidance Sets The Stock Up For A Solid 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)?

Investor sentiment improves as stock rises 18%

The Price Is Right For Schrödinger, Inc. (NASDAQ:SDGR) Even After Diving 26%

Price target decreased by 7.5% to US$43.67

Schrödinger, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Schrödinger, Inc.'s (NASDAQ:SDGR) P/S Still Appears To Be Reasonable

Investor sentiment improves as stock rises 30%

Price target decreased by 14% to US$48.67

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 14% to US$48.67

Price target decreased by 7.0% to US$54.44

Schrödinger, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Investor sentiment deteriorates as stock falls 16%

Schrödinger, New York City College of Technology, and LaGuardia Community College Receives $1 Million Grant from the National Science Foundation to Increase Access to Computational Molecular Modeling Education

Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)?

Executive VP & CTO notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 23%

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 8.4% to US$58.56

Chief Legal & People Officer notifies of intention to sell stock

Is There An Opportunity With Schrödinger, Inc.'s (NASDAQ:SDGR) 49% Undervaluation?

Price target increased by 7.3% to US$55.56

New major risk - Revenue and earnings growth

Independent Director exercised options and sold US$349k worth of stock

Consensus EPS estimates increase from loss to US$0.394 profit

Schrödinger, Inc. Provides Earnings Guidance for the Second Quarter and Full Year Ending December 31, 2023

First quarter 2023 earnings: EPS exceeds analyst expectations

Insufficient new directors

Consensus EPS estimates upgraded to US$0.31 loss

Consensus EPS estimates fall by 21%

Price target decreased by 7.7% to US$51.38

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Executive VP exercised options and sold US$606k worth of stock

Schrödinger, Inc. to Report Q4, 2022 Results on Feb 28, 2023

CEO, President & Director exercised options and sold US$1.1m worth of stock

Forecast to breakeven in 2025

Schrödinger Presents New Preclinical Data Supporting Advancement of CDC7 Inhibitor Development Candidate, SGR-2921

Price target decreased to US$61.00

Price target decreased to US$61.00

Third quarter 2022 earnings released: US$0.56 loss per share (vs US$0.49 loss in 3Q 2021)

Schrödinger, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Schrödinger, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Schrödinger, Inc. Appoints Geoffrey Porges as CFO

Schrödinger: Q2 Earnings Supports Growth Narrative

Schrödinger, Inc. Announces CFO Changes

Schrödinger appoints Dr. Geoffrey Porges as finance chief

No longer forecast to breakeven

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Schrödinger, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Schrödinger, Inc. Announces FDA Clearance of Investigational New Drug Application for SGR-1505, a MALT1 Inhibitor